Effects of intensive glucose lowering in type 2 diabetes - Wikidata - awgldk - TriplyDB

Effects of intensive glucose lowering in type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes

http://www.wikidata.org/entity/Q29547736

about

Autonomic neuropathy in diabetes mellitus The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations Role of insulin in the type 2 diabetes therapy: past, present and future Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Use of metformin in the setting of mild-to-moderate renal insufficiency ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus Pramlintide for diabetes mellitus Glucose targets for preventing diabetic kidney disease and its progression Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus Colesevelam for type 2 diabetes mellitus Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus Colesevelam for type 2 diabetes mellitus Treatment blood pressure targets for hypertension Pramlintide for diabetes mellitus Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus National trends in treatment of type 2 diabetes mellitus, 1994-2007 Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials Impact of diastolic and systolic blood pressure on mortality: implications for the definition of "normal"Standards of medical care in diabetes--2012 Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Complementary and alternative medicine for the treatment of type 2 diabetes Insulin resistance is a cellular antioxidant defense mechanism Epigenetics: a molecular link between environmental factors and type 2 diabetes Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?Interactions between kidney disease and diabetes: dangerous liaisons Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?Recent advances in managing and understanding diabetic nephropathy The EMPA-REG outcome study: critical appraisal and potential clinical implications The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials Report of the Japan diabetes society/Japanese cancer association joint committee on diabetes and cancer, Second report Hypoglycemic agents and potential anti-inflammatory activity SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?Diabetes Dyslipidemia Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metformin

P2860

Q21131270-B2EDDC4B-179A-491F-B444-BEF1AAB1F01A Q21563399-3E4B2EA3-51F2-4DE3-A9F8-3C2DA160CD1B Q22241134-7261FF9B-0FB1-44E3-8618-3CF188062101 Q22241148-B5919026-6CD0-4B95-BB77-D7840EB11CFE Q22241288-85F351A6-FAFD-4DE6-B580-1DB3B7928E11 Q22241290-35E8723F-06D6-49FD-A766-1B4A9930E189 Q22241786-DFC8BD82-91F3-46D3-A113-49ED7ACE3832 Q22250879-81BCAAC0-934B-4D15-A11B-4D1E0E272D06 Q24186667-AD68C875-2F45-4052-A253-665C942179EF Q24186857-E3FE75AC-ABA9-42C8-92FC-6C21A7DF8F29 Q24198925-5353632F-EFB7-480F-91E2-54E08BDD03F0 Q24200376-F1B97C06-A667-42C8-BE2F-601C01F1C730 Q24202334-12CF401D-3C41-476F-958F-CF8D32AAA544 Q24202505-FEB376C4-C800-4CEB-AB32-160BB24A0615 Q24234960-A93EEE79-5FFD-4F94-9D37-ED4F1F436BCC Q24236456-10CEEB7C-B5C4-48CB-93D9-04E14983F982 Q24236703-47E4F01A-3433-470E-9085-F8D5E466AF0B Q24239956-0B8C08B1-066B-4130-A674-64A19DB2A9E7 Q24240172-15C9A6CC-02F5-4D8B-9EB1-E3FA4315C945 Q24241529-BE8AF3F8-283E-4307-B89E-56BED413948C Q24619979-AB5E3FFC-4CEC-466E-BBD6-F3A16D0358D7 Q24628988-08156FF5-C080-495F-A951-0C548F81B899 Q24632396-151D2F45-2E5D-4CE8-B635-C20EBD25ED51 Q24632533-8D68FD60-C240-4874-BD70-D5B1BBBD5F75 Q24642503-A3C924E6-0F21-4DA3-B162-898D1790399E Q24648508-D69D31DB-648F-4E1F-94FB-139303B98C80 Q24650976-29A898D0-88F6-4ED5-A7DB-12D4D058B929 Q24652830-BD620F49-D1B1-4B7C-B313-14FDF7A33330 Q26740247-61C13876-CA7C-46E1-B35F-4069623BE2DD Q26740630-88EA4D16-E9D5-432D-9071-77F722AF5D84 Q26745606-E2A5D4FF-7FCC-4B50-A807-ACE5CC3B9E18 Q26745900-462E9156-E8B3-46EA-A8F0-E3497D77C835 Q26748742-900A7D1F-0BFB-4BEF-855A-9F00F59D052C Q26748870-2DE5C0DA-EEC8-44B0-BE80-6BA32A3B45EC Q26749362-59178366-BC45-45CC-A615-C47D42CA91DB Q26750414-28C04B18-8348-4425-9DE8-B903FE159E88 Q26750510-E4A049F0-6413-4D19-BFD5-34E8CB590385 Q26750905-5D9F94F8-6799-45C0-BC6D-69BD5B5B755A Q26752255-9438A945-1157-4786-968A-8FE893DF5A4A Q26752815-935924CD-4F46-45A5-B56A-19797A8F398A

P2860

Effects of intensive glucose lowering in type 2 diabetes

http://www.wikidata.org/entity/Q29547736

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Effects of intensive glucose lowering in type 2 diabetes

@ast

Effects of intensive glucose lowering in type 2 diabetes

@en

type

label

Effects of intensive glucose lowering in type 2 diabetes

@ast

Effects of intensive glucose lowering in type 2 diabetes

@en

prefLabel

Effects of intensive glucose lowering in type 2 diabetes

@ast

Effects of intensive glucose lowering in type 2 diabetes

@en

P1433

Q29547736-B7373970-FD57-4272-80CB-0C3CC178344F

P1476

Q29547736-3F3BC82D-28CE-46BA-95ED-85DC3058E358

P2093

Q29547736-123B1018-BD28-4739-AE1E-F7DA1579DF5A

Q29547736-37B608B8-46CD-4EF1-ABC7-EA7038D7B8B6

Q29547736-48F89553-4857-43A7-A5AE-AE4C698C1412

Q29547736-5558943D-9896-43CE-B866-9393834803B6

Q29547736-62480F83-D570-430B-BDA3-7DEF1F57B0B7

Q29547736-68FD0023-A40E-4D1A-A84D-728372DCD6CE

Q29547736-72AB7EAD-2BB9-4CA1-ADAC-6BD87C958B2A

Q29547736-75BBF6DE-C94C-4173-92C6-19E8D0394FAF

Q29547736-78F4B142-933C-42E2-8218-32E948AD27A4

Q29547736-7F133135-B014-4D81-AE9B-11E4A7B0F181

P2860

Q29547736-05F3CEC6-C342-4E99-BF13-84B32A5E7221

Q29547736-08D1FA13-4619-49B2-A831-13CD1DAFB637

Q29547736-24223D25-31A3-4C72-93C4-C4E723C9C0F0

Q29547736-4A71D1BD-6BE4-49B9-B660-78115AF2429F

Q29547736-6766206E-F2CE-4C6E-A155-88B2511FFE5F

Q29547736-7568371B-59C4-43EE-BADE-D81401D6D63B

Q29547736-8083969E-DAC1-4DD3-A23D-346A39145519

Q29547736-8E14B7F9-3436-4B03-8C43-C85503090CF1

Q29547736-94896665-54EF-4824-B1FE-7E6308E93AEE

Q29547736-9FC888FD-58AF-4FF6-90B1-F4C4570B269F

P304

Q29547736-2D7450E6-B98F-44AA-9B69-8B8B471F9B76

P31

Q29547736-34093DC9-0B96-4AC8-A266-D163A4F74A3C

P3181

Q29547736-94B6BC00-3297-45DB-98B6-1CBF87ABFBC5

P356

Q29547736-ABF12888-545B-45CF-ACCE-43CACF8B8FB7

P407

Q29547736-42DE0B8F-D9FF-47EC-B01A-DD9CD1B069BB

P433

Q29547736-3FD5D5CD-C74D-43D7-A38B-E109315FE4DE

P478

Q29547736-C9454ADB-0B38-45B5-BC2A-413D9CB112B2

P5008

Q29547736-365382CF-5935-4B48-9610-036147273946

P577

Q29547736-4AC87941-BC50-4D36-A971-DC47E4C7F65A

P698

Q29547736-47242FAC-9AD9-456E-9DEE-1E515A84B89C

P921

Q29547736-760bbf8c-4800-297c-28f5-2496133bd7b9

Q29547736-8E7771B9-F164-47EE-B75F-BF1A91138EFE

Q29547736-cb24cb54-f774-458d-acd1-9c0b92b78cc5

P932

Q29547736-48718B75-512A-4E7A-8185-B5B9FB645B57

P3181

P356

P1433

The New England Journal of Medicine

P1476

Effects of intensive glucose lowering in type 2 diabetes

@en

P2093

Bigger JT

http://www.w3.org/2001/XMLSchema#string

Buse JB

http://www.w3.org/2001/XMLSchema#string

Byington RP

http://www.w3.org/2001/XMLSchema#string

Cushman WC

http://www.w3.org/2001/XMLSchema#string

Friedewald WT

http://www.w3.org/2001/XMLSchema#string

Genuth S

http://www.w3.org/2001/XMLSchema#string

Gerstein HC

http://www.w3.org/2001/XMLSchema#string

Goff DC Jr

http://www.w3.org/2001/XMLSchema#string

Grimm RH Jr

http://www.w3.org/2001/XMLSchema#string

Ismail-Beigi F

http://www.w3.org/2001/XMLSchema#string

P2860

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial

Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.

Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis.

Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.

P304

2545-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

19365

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0802743

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

358

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2008-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18539917

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

therapeutic failure

P932

4551392

http://www.w3.org/2001/XMLSchema#string